Autopsy report · NCT01546688
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
Cause of deathNo reason given
Life of this trial
- Registered 3 years 4 months after it had already started.
- Ran for about 2 years 9 months before it stopped.
- 41 participants enrolled.
- Results were posted on the registry 1 year 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Eisai Limited
- Sponsor type
- Industry
- Conditions
- Epilepsy
- Interventions
- Zonisamide at targeted daily doses of 100-500 mg/day; Placebo administered to match targeted daily doses of 100-500 mg/day
- Participants
- 41
- Sites
- 36
- Countries
- Germany, Hungary, Italy, Netherlands, Poland, Switzerland, United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.